Last reviewed · How we verify
DNA degradation once daily
This drug promotes the degradation of DNA, likely through enzymatic or chemical mechanisms that break down DNA strands.
At a glance
| Generic name | DNA degradation once daily |
|---|---|
| Also known as | DNase once daily, lytics once daily |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
DNA degradation therapies work by facilitating the breakdown of cellular DNA, which can be used to eliminate rapidly dividing cells or cells with compromised DNA integrity. The once-daily dosing suggests a formulation designed for systemic delivery and sustained effect. The specific molecular mechanism—whether through nuclease activity, topoisomerase inhibition, or another pathway—is not clearly specified in the available information.
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs (PHASE3)
- Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema (PHASE4)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DNA degradation once daily CI brief — competitive landscape report
- DNA degradation once daily updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI